PMID- 16391407
OWN - NLM
STAT- MEDLINE
DCOM- 20060329
LR  - 20181113
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 29
IP  - 3
DP  - 2005 Dec
TI  - Intravenous immunoglobulin and atherosclerosis.
PG  - 311-9
AB  - Several inflammatory and immunological factors have been established as important 
      contributors to atherogenesis. Among these, oxidized low-density lipoprotein 
      (oxLDL) play a central role in the initiation and progression of atherosclerotic 
      lesions. In atherosclerotic lesions, oxLDL was also found to co-localize with 
      beta2-glycoprotein I (beta2-GPI). Immunoglobulin (Ig)G autoantibodies against 
      beta2-GPI complexed with oxLDL are pro-atherogenic because they increase uptake 
      of the complexes by macrophages. In contrast, IgM natural anti-oxLDL antibodies 
      derived from atherosclerosis-prone apolipoprotein E (ApoE) deficient mice reduced 
      incidence of atherosclerosis. Such anti-oxLDL antibodies have been found in 
      humans, and the accumulating evidences seem to support the idea that anti-oxLDL 
      antibodies have a protective role for atherogenesis. Intravenous immunoglobulins 
      (IVIgs) contain natural anti-oxLDL antibodies and infusion of IVIg into 
      ApoE-deficient mice has been reported to decrease atherosclerosis. The 
      anti-atherogenic property of IVIg may be derived from non-antigen-specific 
      antibody binding to FCgamma receptors, which blocks foam cell formation of 
      macrophages. Several other possible mechanisms are also discussed.
FAU - Matsuura, Eiji
AU  - Matsuura E
AD  - Department of Cell Chemistry, Okayama University Graduate School of Medicine, 
      Dentistry, and Pharmaceutical Sciences, Okayama, Japan. 
      eijimatu@md.okayama-u.ac.jp
FAU - Kobayashi, Kazuko
AU  - Kobayashi K
FAU - Inoue, Katsumi
AU  - Inoue K
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Autoantibodies)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 0 (oxidized low density lipoprotein)
SB  - IM
MH  - Animals
MH  - Atherosclerosis/*drug therapy/*immunology/physiopathology
MH  - Autoantibodies/*immunology
MH  - Foam Cells/immunology/metabolism
MH  - Glycoproteins/immunology/metabolism
MH  - Humans
MH  - Immunoglobulins, Intravenous/immunology/*therapeutic use
MH  - Lipoproteins, LDL/*immunology/metabolism
MH  - Mice
MH  - beta 2-Glycoprotein I
RF  - 50
EDAT- 2006/01/05 09:00
MHDA- 2006/03/30 09:00
CRDT- 2006/01/05 09:00
PHST- 2006/01/05 09:00 [pubmed]
PHST- 2006/03/30 09:00 [medline]
PHST- 2006/01/05 09:00 [entrez]
AID - CRIAI:29:3:311 [pii]
AID - 10.1385/CRIAI:29:3:311 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2005 Dec;29(3):311-9. doi: 10.1385/CRIAI:29:3:311.